Global Biopharmaceutical Fermentation Systems Market – Snapshot

The global biopharmaceutical fermentation systems market was valued at around US$ 10.0 Bn in 2017 and is anticipated to expand at a CAGR of more than 6.0% from 2018 to 2026 to reach a value of around US$ 17.8 Bn in 2026. Emphasis on the development and marketing of innovative products and solutions such as single-use systems and continuous bioprocessing is likely to drive the biopharmaceutical fermentation systems market market. Moreover, expansion by key players in emerging markets through contracts and collaborations is anticipated to propel the market in the coming years. For instance, expansion in Asia Pacific through flexible and modular manufacturing facility solutions and collaboration with biopharmaceutical manufacturers to develop and improve bioprocess products.

biopharmaceutical fermentation systems market

In terms of application, the recombinant proteins segment held a major market share in 2017. High reliance on microbial systems for recombinant protein production contributed toward the leading share of the segment. Increase in investment in research activities and introduction of new protein therapeutics have significantly contributed to the development of recombinant therapeutic antibodies and proteins. Moreover, rise in the number of clinical trials in the pharmaceutical industry have boosted the segment in past few years. The recombinant proteins segment is expected to dominate the market during the forecast period, owing to an increased focus on developing innovative fusion protein and antibody-drug conjugates products.

Based on end-user, the biopharmaceutical companies segment accounted for a major market share in 2017. Well-equipped infrastructure and strong expertise have led to the dominant share of the segment. Biopharmaceutical companies such as Shire plc, AstraZeneca, Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Amgen have a wide portfolio of biological drugs. These companies are investing in the development of new biotherapeutics. With near-term patent expiry of blockbuster biologicals, biosimilars and biobetters are estimated to enter the market. This is expected to increase the adoption of microbial fermentation systems among biopharmaceutical companies. Furthermore, these key manufacturers are expanding their operations in emerging regions such as Asia Pacific and Latin America for better market access and regulatory compliance.

In terms of region, the biopharmaceutical fermentation systems market is dominated by developed economic regions such as North America and Europe, owing to rapid development of biopharmaceuticals-derived techniques in these two regions. Additionally, significant research support in terms of infrastructure and funding has driven the biopharmaceutical fermentation systems market in the past decade. The market in emerging regions, such as Asia Pacific and the Rest of the World, is expected to expand at a rapid pace due to robust economic development and increase in demand for therapeutics in these regions Owing to reforms and economic growth, developing countries have been successful in attracting investment from prominent players. These regions allow market players to increase customer base and expand their business. Moreover, key players are introducing automation technologies and solutions to integrate microbial fermentation systems in order to analyze and monitor culture process and increase efficacy of the production process. For instance, GE Healthcare has collaborated with Zenith Technologies and Emerson Process Management to offer automation solutions through its FlexFactory and KUBio biopharmaceutical manufacturing facilities. These technological advances in microbial fermentation systems are likely to fuel the adoption of microbial cell systems for the production of biopharmaceuticals in the near future.

Prominent players operating in the global biopharmaceutical fermentation systems market include GE Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius StedimBiotech, Merck KGaA, Eppendorf AG, F. Hoffmann-La Roche Ltd., Nova Biomedicals, Lonza, and Becton, and Dickinson and Company. Sartorius Stedim Biotech has been offering innovative solutions for microbial fermentation such as large-scale single-use microbial fermenters, process monitoring systems, and filtration and chromatography systems over the years. The company is a leading supplier of microbial fermentation systems. Another major player is Merck KGaA, which has a wide portfolio of bioprocess products and solutions. Merck has expertise in downstream products with single-use and reusable filtration and chromatography systems and consumables. There are numerous small- and medium-scale suppliers of bioprocess and other fermentation products, which has led to a fragmented market. However, among biopharmaceutical companies and CDMOs, the top five players are major suppliers of microbial bioprocess solutions and products. They account for 45% to 50% of the revenue generated from these end-users.

Global Biopharmaceutical Fermentation Systems Market: Overview

This report analyzes the global biopharmaceutical fermentation systems market in terms of its current and future scenario. Microbial cell systems have been in use for biopharmaceutical production since the introduction of recombinant insulin. Ease of gene translation and bioproduction process has contributed to the significant adoption of microbial systems in biopharmaceutical production. Rise in research and development activities, technological advancements, increase in awareness about products, and new product launches are some of the factors likely to drive the biopharmaceutical fermentation systems market in the near future.

This report on the global biopharmaceutical fermentation systems market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product, application, end-user, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. In addition, the section comprises a competitive matrix and company profiles with a business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the biopharmaceutical fermentation systems market.

Global Biopharmaceutical Fermentation Systems Market: Key Segments

Based on product, the global biopharmaceutical fermentation systems market has been segmented into upstream products ( fermenters, bioprocess analyzers, process monitoring devices, culture & media preparation, culture media, buffers & inducers, other upstream products) and downstream products (filtration & separation systems, chromatography, consumables & accessories, and other downstream products). In terms of application, the market has been classified into recombinant proteins, monoclonal antibodies, antibiotics, probiotics, and others. Based on end-user, the market has been segmented into biopharmaceutical companies, contract manufacturing organizations, contract research organizations, academic research institutes, food industry, and others.  The global biopharmaceutical fermentation systems market has been analyzed based on technology trends, expenditure on emerging technologies, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Biopharmaceutical Fermentation Systems Market: Regional Outlook

In terms of region, the global biopharmaceutical fermentation systems market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period 2018-2026, considering 2017 as the base year. This report also covers the competitive scenario of the market in these regions.

 

Companies Mentioned in Report

The report profiles major players operating in the global biopharmaceutical fermentation systems market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report are GE Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius StedimBiotech, Merck KGaA, Eppendorf AG, F. Hoffmann-La Roche Ltd., Nova Biomedicals, Lonza, and Becton, and Dickinson and Company.

The global biopharmaceutical fermentation systems market has been segmented as follows:

Biopharmaceutical Fermentation Systems Market, by Product

  • Upstream Products
    • Fermenters
    • Bioprocess Analyzers
    • Process Monitoring Devices
    • Culture & Media Preparation
    • Culture Media, Buffers & Inducers
    • Other Upstream Products
  • Downstream Products
    • Filtration & Separation Systems
    • Chromatography
    • Consumables & Accessories
    • Other Downstream Products

Biopharmaceutical Fermentation Systems Market, by Application

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Antibiotics
  • Probiotics
  • Others (Amino Acids, Enzymes, Polysaccharides, etc.)

 Biopharmaceutical Fermentation Systems Market, by End-user

  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations
  • Contract Research Organizations
  • Academic Research Institutes
  • Food Industry
  • Others

Biopharmaceutical Fermentation Systems Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia & New Zealand
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Israel
    • Rest of Middle East & Africa
.